Point72 Asset Management L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 90.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 857,853 shares of the company's stock after purchasing an additional 406,535 shares during the quarter. Point72 Asset Management L.P. owned 1.26% of EyePoint Pharmaceuticals worth $6,391,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. ProShare Advisors LLC lifted its holdings in EyePoint Pharmaceuticals by 70.7% in the fourth quarter. ProShare Advisors LLC now owns 21,679 shares of the company's stock valued at $162,000 after acquiring an additional 8,981 shares during the period. Patient Square Capital LP lifted its holdings in EyePoint Pharmaceuticals by 3.6% in the fourth quarter. Patient Square Capital LP now owns 1,410,331 shares of the company's stock valued at $10,507,000 after acquiring an additional 48,352 shares during the period. Nuveen Asset Management LLC lifted its holdings in EyePoint Pharmaceuticals by 7.6% in the fourth quarter. Nuveen Asset Management LLC now owns 183,949 shares of the company's stock valued at $1,370,000 after acquiring an additional 13,048 shares during the period. Millennium Management LLC acquired a new position in EyePoint Pharmaceuticals in the fourth quarter valued at approximately $3,324,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in EyePoint Pharmaceuticals by 35.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,022 shares of the company's stock valued at $276,000 after acquiring an additional 9,593 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.
EyePoint Pharmaceuticals Price Performance
Shares of EYPT stock opened at $6.10 on Tuesday. EyePoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $13.99. The company has a market cap of $419.75 million, a price-to-earnings ratio of -3.05 and a beta of 1.58. The stock has a 50 day simple moving average of $5.88 and a 200-day simple moving average of $7.25.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $24.50 million during the quarter, compared to analysts' expectations of $8.84 million. Analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on EYPT. HC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Chardan Capital decreased their price target on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, Mizuho reduced their target price on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.38.
Get Our Latest Analysis on EYPT
EyePoint Pharmaceuticals Profile
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More
Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
